Profit Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Profit Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,306	Closed	-$323K	–	79
2023 Q4	$323K	Hold	10,306	–	–	0.18%	75
2023 Q3	$215K	Sell	10,306 -523	-5%	-$14.2K	0.15%	72
2023 Q2	$259K	Sell	10,829 -179	-2%	-$3.98K	0.17%	73
2023 Q1	$207K	Hold	11,008	–	–	0.14%	75
2022 Q4	$175K	Hold	11,008	–	–	0.12%	75
2022 Q3	$180K	Hold	11,008	–	–	0.14%	77
2022 Q2	$155K	Sell	11,008 -2,508	-19%	-$46.8K	0.11%	78
2022 Q1	$328K	Buy	13,516 +1,844	+16%	+$44.6K	0.2%	74
2021 Q4	$273K	Sell	11,672 -500	-4%	-$10.1K	0.17%	79
2021 Q3	$203K	Hold	12,172	–	–	0.14%	86
2021 Q2	$295K	Hold	12,172	–	–	0.16%	81
2021 Q1	$314K	Hold	12,172	–	–	0.18%	78
2020 Q4	$651K	Sell	12,172 -9,749	-44%	-$484K	0.42%	49
2020 Q3	$905K	Buy	+21,921	New	+$947K	0.56%	64

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Profit Investment Management's ACAD Position: Q1 2024 in Review

Profit Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 10,306 shares — an estimated $323K sold.

Profit Investment Management first reported a position in ACAD in Q3 2020 and held it in 14 quarters. The position peaked at $905K in Q3 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Profit Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Profit Investment Management sold 10,306 Acadia Pharmaceuticals shares in Q1 2024, an estimated $323K.
Profit Investment Management first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 14 quarters.
Profit Investment Management's Acadia Pharmaceuticals position peaked at $905K in Q3 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Profit Investment Management's 13F filing for Q1 2024, filed 11 Apr 2024.